Jul. 14 at 7:36 PM
$LCTX there is no doubt that FDA will require years of studies, over three phases, their standard protocol, and so the new COR cells will take some time to develop. I for when I’m glad that we are doing this, and find it remarkable that we’re doing it at such low cost.
We now have a series of potential products with huge markets. I anticipate that, once Opregen is producing steady income, we are going to have plenty of money to develop these lines. And, perhaps more importantly, we are going to have enough money to expand the number of new lines, as well.
So in addition to a big shift in our stock price as Opregen produces income (the actual income will finally make valuation easy), I anticipate that at some point we are going to have exponential growth. 
If instead, we are bought by Roche, that exponential growth might be accelerated even more, because Roche can probably afford to develop even faster than the Opregen income stream allows.
I’m fine with it, either way.
